AtaiBeckley shares jumped 64.70% after hours following reports that Eli Lilly is in talks to acquire the psychedelic drugmaker at a premium.
AtaiBeckley Inc.
(NASDAQ:ATAI) shares are trending on Thursday.
Lilly Eyes Acquisition At A Premium Shares of the New York-based psychedelic drugmaker jumped 64.70% to $8.83 after the bell.
On Wednesday, Reuters, citing Bloomberg News, reported Eli Lilly and Co.
(NYSE:LLY) is in talks to acquire AtaiBeckley, with a deal possibly announced as soon as this week.
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Eli Lilly agrees to $3.8B psychedelic buy
Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News
Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari
Eli Lilly comprará biofarmacêutica voltada a transtornos mentais por US$ 2,8 bilhões
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant…
Lilly will acquire AtaiBeckley in a deal worth up to $3.8 billion, adding late-stage depression therapies to its mental health…
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its…
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be…
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
